NADAL® Lyme Borreliosis IgG/IgM test cassette, 10 gab. TIKAI PROFESIONĀLAI LIETOŠANAI!

The NADAL® Lyme Borreliosis IgG/IgM Test is a rapid qualitative screening test for the detection of human IgG and IgM to European strains of Borrelia in human serum and plasma. The test is intended for use as an aid in the diagnosis of Lyme disease, also known as Lyme borreliosis, and is designed for professional use only. However, in the case of a positive result, the NADAL® Lyme Borreliosis IgG/IgM Test does not enable the stage of the disease to be determined.

Lyme disease or Lyme borreliosis is caused by the spirochete Borrelia burgdorferi sensu lato, which is transmitted by ticks. Contagious ticks, infected by Borrelia burgdorferi sensu lato, are mainly found in North America (Ixodes scapularis or Ixodes pacificus) and in temperate areas of Western Europe (Ixodes ricinus). European tick species are vectors of European Borrelia strains, such as B. burgdorferi sensu stricto, B. afzelii, B. garinii  as well as B. spielmanii and B bavariensis, which are also known to be pathogenic.
B. valaisiana and B. lusitaniae are also considered to be potentially pathogenic strains. Due to the high similarity amongst Borrelia strains, IgG and IgM directed against different Borrelia species cross-react with the antigen cocktail of the NADAL® Lyme Borreliosis IgG/IgM Test - at least in the case of European strains.
In 30% to 80% of cases, a skin rash (erythema chronicum migrans) is the first clinical sign of the infection, appearing after 3 to 10 days at the site of the tick bite. Between 1 and 3 months later, the first neurological signs, such as a headache or severe disorders like myelitis, appear - even in the absence of erythema chronicum migrans. Patients may also develop severe complications, such as intermittent attacks of articular arthritis, myocarditis or acrodermatitis much later, even several years after the primary infection.